Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.
about
Atrial fibrillation in women: treatmentEffect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial.Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation.Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.Direct factor Xa inhibitor edoxaban: from bench to clinical practice.Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists.Impact of PharmaNet-Based Admission Medication Reconciliation on Best Possible Medication Histories for Warfarin.Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.A before and after study of warfarin monitoring in a single region as part of the Scottish patient safety programme in primary care.Venous thromboembolism among HIV-positive patients and anticoagulation clinic outcomes integrated within the HIV primary care setting.Croatia needs a registry of patients undergoing direct current cardioversion for persistent atrial fibrillation/flutter.Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?Warfarin: better the devil you know.
P2860
Q30241862-4F3A3B4A-D474-4592-BE06-3653534F5460Q37150903-3D4D4695-A716-4200-A9D5-8E1824D1A793Q37578264-58A99599-7DEA-4F52-8FE5-D32F0BC3ED3AQ38156339-52978933-FE92-4FBD-ABAB-77589925E36AQ38287849-F06F621A-EC37-41F3-9CD5-50A133D0512CQ38631413-BA7F711D-2CDE-40F8-A119-07D545B8B211Q38867977-7E742CB2-BABE-4A07-AECA-D3B23359477AQ39003342-5710D024-FE21-47D6-94E3-DEFDF1758639Q39326279-3429585C-EF66-467A-B482-C081C0BC3AC9Q40697822-11028978-6675-4CFD-8024-57E81AB66FF9Q41653892-F00FDE68-69FF-4482-9AF6-E965A9F28781Q42388117-85E8D3AD-A00E-4C20-8F94-4D43041A2E5AQ44027927-54CDE0B1-D983-4C5C-AF49-805E523185FEQ48563042-FF9765AE-47E6-4C1B-9476-FEAD0C2816AFQ48951317-82A436B3-683E-4CB9-A3FE-1C464DA26CD6Q49347395-134030C7-C657-4B7B-B700-5C891677BAD1
P2860
Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Vitamin K antagonists and time ...... nd strategies for improvement.
@en
type
label
Vitamin K antagonists and time ...... nd strategies for improvement.
@en
prefLabel
Vitamin K antagonists and time ...... nd strategies for improvement.
@en
P2860
P1476
Vitamin K antagonists and time ...... nd strategies for improvement.
@en
P2860
P2888
P304
P356
10.1007/S11239-013-0900-5
P50
P577
2013-04-01T00:00:00Z